Immatics
Join Immatics in advancing cancer immunotherapy through cellular therapies targeting PRAME. The role involves performing specialized cell manipulation and testing procedures in a GMP-compliant environment to support clinical manufacturing.
Headquarters
Tübingen, Baden-Württemberg, Germany
Company Size
201-500 employees
Founded
2000
Immatics is the global leader in precision targeting of PRAME, a cancer-associated antigen expressed in more than 50 cancer types. The company develops PRAME-targeted cell therapies (including TCR T-cell therapies) and TCR bispecific product candidates, with an active clinical pipeline spanning indications such as melanoma, lung, ovarian, breast, and endometrial cancers. Immatics combines deep expertise in immunology and drug development to advance novel treatments for patients with significant unmet medical need.
Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate
2 hours ago
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot (NASDAQ:IMTX)
4 days ago
Immatics (NASDAQ:IMTX) Sees Strong Trading Volume - Here's What Happened
2 days ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Immatics.
Immatics didn’t post a salary, so this is our estimate from similar listings.
87% above the average for this role
Is Immatics’ 2025 Loss and PRAME Pipeline Push Altering The Investment Case For Immatics (IMTX)?
3 days ago